I disagree (even though I suspect you're helming an Astrea 42 atm).
IMO we need cash flow adequate to the needs of our R&D and production program. That's all. Noone's expecting dividends atm.
We don't have (much of) the cash, but we do have partners. And the CEO's flagged other finance sources. I see our relationship with Oaktree as working.
We don't need to get 'ahead' of the bunch. We just need to avoid being swallowed by them, & the emerging value will 'emerge'.
The development timeframes for our products are now real IMO, but I appreciate they're not as tightly concatenated as you'd like. Personally I'm OK with that, for the time being.
Cheers
Cell Therapy News/Articles, page-15695
-
- There are more pages in this discussion • 2,126 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
-0.055(4.66%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.18 | $1.13 | $4.824M | 4.236M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 25589 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 17/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |